Versartis (NASDAQ: VSAR) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.
Earnings and Valuation
This table compares Versartis and Exelixis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Exelixis||$191.45 million||46.98||-$70.22 million||$0.49||62.04|
This is a breakdown of recent ratings and target prices for Versartis and Exelixis, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Versartis currently has a consensus price target of $5.63, suggesting a potential upside of 155.68%. Exelixis has a consensus price target of $31.71, suggesting a potential upside of 4.32%. Given Versartis’ higher possible upside, research analysts plainly believe Versartis is more favorable than Exelixis.
Volatility & Risk
Versartis has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
This table compares Versartis and Exelixis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
49.2% of Versartis shares are held by institutional investors. Comparatively, 81.2% of Exelixis shares are held by institutional investors. 10.9% of Versartis shares are held by company insiders. Comparatively, 5.1% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Exelixis beats Versartis on 9 of the 12 factors compared between the two stocks.
Versartis Company Profile
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD. The Company may develop somavaratan for additional growth disorders, such as idiopathic short stature (ISS), small for gestational age (SGA) and Turner Syndrome. Somavaratan is engineered using XTEN technology to extend the residence time in the bloodstream by reducing the clearance of recombinant human growth hormone (rhGH) from the body by the two primary mechanisms, kidney filtration and receptor mediated clearance.
Exelixis Company Profile
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.